Climb Bio (CLYM) AI Stock Analysis

• Market Cap: $100.01M
• Dividend Yield: N/A
• Average Volume (3M): 314.57K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.78
• Revenue Growth: N/A
• EPS Growth: -61.95%
• Country: US
• Employees: 17
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.31
• Shares Outstanding: 67,575,770
• 10 Day Avg. Volume: 210,088
• 30 Day Avg. Volume: 314,574
• PEG Ratio: 0.09
• Price to Book (P/B): 0.50
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.29
• Enterprise Value/Market Cap: 0.67
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.20
• 1Y Price Target: $9.00
• Price Target Upside: 508.11% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 41 Neutral
• Price Target: ―

Climb Bio's stock score is primarily driven by its financial performance, reflecting the company's developmental challenges with negative income and cash flow. Despite strong equity and cash reserves, the technical indicators show a bearish trend, and the valuation reflects typical early-stage biotech characteristics with a negative P/E ratio. The absence of significant earnings call data or corporate events means the focus remains on financial stability and potential for future growth.

Positive Factors

Clinical Trials

The company received FDA clearance for the trial, which was supported by compelling early data showing treatment with budo led to complete remission.

Market Positioning

CLYM is viewed as a promising early entrant into the CD19-targeting space for autoimmune diseases, with validated clinical and commercial potential.

Pipeline Development

CLYM plans to initiate multiple trials for budo in different indications, showing a strong pipeline development strategy.

Negative Factors

Market Competition

As a new entrant, CLYM may face significant competition in the CD19-targeting space for autoimmune diseases.

Climb Bio Business Overview & Revenue Model

Company Description

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

How the Company Makes Money

Climb Bio Financial Statement Overview

Summary

Climb Bio is in its development phase, with significant R&D expenses and no revenue. The company has strong equity and cash reserves providing stability, but negative income and cash flow indicate challenges in achieving profitability without successful product development.

Income Statement

Climb Bio has experienced consistent losses with no revenue generation, typical for a biotechnology company in development stages. The company's EBIT and EBITDA margins are negative, reflecting ongoing operational expenses without offsetting revenue. The net income is consistently negative, highlighting significant operational challenges.

Balance Sheet

Climb Bio maintains a strong equity position with low debt, as indicated by a low debt-to-equity ratio. The company has substantial cash reserves, enhancing its financial stability. However, the lack of revenue generation and continuous accumulation of losses could impact long-term sustainability if not addressed.

Cash Flow

The company has negative operating and free cash flows, which are expected for a biotech firm without commercial products. The free cash flow has not shown growth, and reliance on financing activities is evident. This indicates potential cash burn risks if external funding sources diminish.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	-30.36M	-40.27M	-45.13M	-35.67M	-11.77M
Net Income	-73.90M	-35.12M	-45.24M	-47.48M	-20.67M
Balance Sheet
Total Assets	217.19M	110.47M	134.99M	173.24M	24.63M
Cash, Cash Equivalents and Short-Term Investments	150.92M	106.80M	123.57M	136.48M	20.49M
Total Debt	532.00K	349.00K	480.00K	0.00	0.00
Total Liabilities	5.31M	2.87M	6.28M	6.04M	3.06M
Stockholders Equity	211.88M	107.60M	128.72M	167.20M	21.57M
Cash Flow
Free Cash Flow	-15.56M	-20.60M	-37.37M	-36.07M	-14.10M
Operating Cash Flow	-15.56M	-20.60M	-37.37M	-36.07M	-14.10M
Investing Cash Flow	-121.09M	68.98M	34.44M	-114.97M	8.08M
Financing Cash Flow	130.73M	841.00K	0.00	177.23M	4.92M

Climb Bio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.48
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLYM, the sentiment is Positive. The current price of 1.48 is above the 20-day moving average (MA) of 1.34, above the 50-day MA of 1.28, and below the 200-day MA of 2.09, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 61.54 is Neutral, neither overbought nor oversold. The STOCH value of 54.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLYM.

Climb Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CCCC	53 Neutral	$171.84M	―	-45.55%	―	98.56%	37.97%
Sector *	52 Neutral	$7.61B	0.04	-62.94%	2.44%	16.14%	0.33%
ORMP	47 Neutral	$93.94M	21.10	-18.37%	―	-100.00%	―
CLYM	41 Neutral	$100.01M	―	-62.04%	―	―	-61.95%
IMUX	37 Underperform	$95.53M	―	-246.26%	―	―	51.02%
VOR	33 Underperform	$261.17M	―	-125.43%	―	―	2.98%

Climb Bio Corporate Events

Climb Bio Expands Board with New Director Appointments

On March 27, 2025, Climb Bio, Inc. experienced changes in its board of directors with the resignation of Simon Tate and the decision of Adam Rosenberg not to seek re-election. Both directors clarified that their decisions were not due to disagreements with the company’s operations or policies. On March 28, 2025, the board expanded from seven to eight members, electing Alexander (Bo) Cumbo and Kimberlee (Kim) Drapkin as new directors. Cumbo and Drapkin will serve in various committee roles and receive compensation in line with the company’s non-employee director compensation policy. These changes are part of the company’s ongoing governance adjustments and may influence its strategic direction.